NCT04739423View on ClinicalTrials.gov

A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 28, 2021

Primary Completion Date

July 4, 2022

Study Completion Date

August 31, 2022

Conditions
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
Interventions
DRUG

clenbuterol (CST-103), nadolol (CST-107), matching placebo

clenbuterol (CST-103) and matching placebo orange capsules; nadolol (CST-107) and matching placebo white capsules

Trial Locations (7)

2006

The University of Sydney, Sydney

3050

Royal Melbourne Hospital, Melbourne

8011

NZBRI, Christchurch

QLD 4066

Wesley Medical Research Ltd, Brisbane

S75 3DL

MAC, Tankersley

FY2 0JH

MAC, Blackpool

M13 9NQ

MAC, Manchester

Sponsors
All Listed Sponsors
lead

CuraSen Therapeutics, Inc.

INDUSTRY

NCT04739423 - A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders | Biotech Hunter | Biotech Hunter